Date: 2017-12-06
Type of information: Nomination
Compound: member of the supervisory board
Company: Nosopharm (France)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 6, 2017, Nosopharm announced that Gilles Alberici and Marie-Paule Richard join its supervisory board. These new appointments consolidate the company ‘s position as an innovative player in the field of antibacterial and antifungal treatments. Gilles Alberici will be its new chairman. They join Nosopharm’s existing supervisory board members: Gwenaël Hamon (Kreaxi, investment manager), Franck Lescure (Auriga Partners, partner) and Bernard Rivière (historic shareholder).
- Gilles Alberici, PharmD, PhD, has 30 years experience in the European pharmaceutical industry, having established several innovative biopharmaceutical companies. He joined the Mérieux Group in 1986 and founded IMTIX, a company specializing in immunosuppression, in 1994. In 2000, he founded OPi, a company dedicated to rare and serious diseases. Since 2007, he has been chairman of Octalfa, an independent, family-owned company specializing in the creation, management and funding of life sciencescompanies. In 2008, Octalfa established the Dominique & Tom Alberici-Octalfa corporate foundation, which supports projects aimed at improving care for disabled people and cancer patients.
- For more than 30 years, Marie-Paule Richard, a doctor of medicine, has worked in numerous executive positions in the clinical development of anti-infective agents (antibiotics, antivirals, antifungals) and therapeutic and preventative vaccines at international pharmaceutical and biotechnological companies, including BMS, Aventis Pharma, GSK, Sanofi Pasteur and Crucell. She was chief medical officer at AiCuris before joining TiGenix S.A.U. in Madrid in 2014 as chief medical officer, focusing on allogenic cell therapy. Marie-Paule is a member of the board of Tigenix Inc. based in Cambridge, Massachusetts, USA. She has a medical degree from the University of Nancy, France, and certifications in clinical immunology, pharmacology and pharmacokinetics.
- NOSO-502 is the most advanced molecule in Nosopharm’s portfolio. It inhibits bacterial translation with a new mechanism of action. Its main objective is the treatment of nosocomial infections with Enterobacteriaceae, including carbapenem-resistant (CRE) and polymyxin-resistant Enterobacteriaceae. Nosopharm aims to submit an IND authorization application for NOSO-502 in 2020 with the objective of using it in humans that year. The company will also file patent applications to cover new classes of anti-infective therapies before the end of 2018.
Financial terms:
Latest news:
Is general: Yes
